Viewing Study NCT06956092


Ignite Creation Date: 2025-12-24 @ 3:34 PM
Ignite Modification Date: 2025-12-30 @ 7:36 AM
Study NCT ID: NCT06956092
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-05-02
First Post: 2025-04-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Sponsor: Zhengzhou University
Organization:

Study Overview

Official Title: Prospective Clinical Study of Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Status: NOT_YET_RECRUITING
Status Verified Date: 2025-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: Glofitamab
Brief Summary: The goal of this clinical trial is to learn if Glofitamab works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of Glofitamab treatment. The main questions it aims to answer are:

* Does Glofitamab treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment?
* What medical problems do participants have when receiving Glofitamab treatment?

In this investigator-initiated, single-arm clinical trial, participants will:

* Receive Glofitamab treatment as per the instructions in the package insert.
* Visit the clinic as instructed for checkups and tests.
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: